Greenwich LifeSciences (NASDAQ:GLSI) CEO Snehal Patel Buys 2,900 Shares

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel acquired 2,900 shares of the firm’s stock in a transaction on Tuesday, December 30th. The stock was acquired at an average cost of $21.73 per share, with a total value of $63,017.00. Following the acquisition, the chief executive officer owned 5,595,102 shares of the company’s stock, valued at $121,581,566.46. This trade represents a 0.05% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Snehal Patel also recently made the following trade(s):

• On Thursday, December 18th, Snehal Patel bought 4,100 shares of Greenwich LifeSciences stock. The stock was bought at an average price of $12.62 per share, for a total transaction of $51,742.00.
• On Tuesday, November 25th, Snehal Patel purchased 4,600 shares of Greenwich LifeSciences stock. The shares were purchased at an average price of $8.37 per share, with a total value of $38,502.00.
• On Friday, November 7th, Snehal Patel acquired 10,600 shares of Greenwich LifeSciences stock. The stock was purchased at an average cost of $8.43 per share, for a total transaction of $89,358.00.
• On Friday, October 31st, Snehal Patel bought 2,300 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $9.26 per share, with a total value of $21,298.00.

Greenwich LifeSciences Price Performance

Shares of GLSI stock opened at $21.01 on Friday. Greenwich LifeSciences, Inc. has a 12-month low of $7.78 and a 12-month high of $30.82. The firm has a market capitalization of $290.99 million, a price-to-earnings ratio of -14.39 and a beta of 1.46. The business has a 50 day simple moving average of $10.91 and a 200 day simple moving average of $10.85.

Greenwich LifeSciences (NASDAQ:GLSI) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.30). On average, equities analysts anticipate that Greenwich LifeSciences, Inc. will post -0.8 EPS for the current fiscal year.

Wall Street Analyst Weigh In

GLSI has been the topic of several recent research reports. Wall Street Zen upgraded shares of Greenwich LifeSciences from a “sell” rating to a “hold” rating in a research note on Saturday, December 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Greenwich LifeSciences in a report on Monday. Finally, HC Wainwright boosted their price target on shares of Greenwich LifeSciences from $39.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $47.50.

Key Greenwich LifeSciences News

Here are the key news stories impacting Greenwich LifeSciences this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and raised the price target to $50 (from $39), signaling strong upside expectations from the firm’s analyst Y. Chen. This upgrade/target lift can support positive momentum and investor interest. Greenwich LifeSciences price target raised to $50 from $39 at HC Wainwright
• Positive Sentiment: Company claims a new milestone in breast cancer prevention — a pipeline development that could materially affect long-term revenue potential and justify the higher analyst valuation if substantiated by data. New milestone in breast cancer prevention claimed by Greenwich
• Neutral Sentiment: Trading and technical context: the shares are volatile — recent price is well above the 50- and 200-day moving averages (~$10.7), and volume today is slightly below average. That technical gap can amplify reactions to news (both positive and negative). Greenwich LifeSciences stock profile
• Negative Sentiment: HC Wainwright’s detailed forecasts project consistent quarterly losses and a wider FY2026 EPS loss (~$1.24) compared with the current consensus (~$0.80). Larger-than-expected multi-quarter losses increase execution and financing risk, which can weigh on the stock despite the buy rating. HC Wainwright estimates and analyst note

Hedge Funds Weigh In On Greenwich LifeSciences

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Citadel Advisors LLC raised its holdings in shares of Greenwich LifeSciences by 52.1% in the third quarter. Citadel Advisors LLC now owns 20,942 shares of the company’s stock worth $208,000 after buying an additional 7,174 shares during the period. Vanguard Group Inc. raised its position in Greenwich LifeSciences by 4.9% during the 3rd quarter. Vanguard Group Inc. now owns 282,181 shares of the company’s stock worth $2,808,000 after buying an additional 13,179 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Greenwich LifeSciences in the 2nd quarter valued at $509,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Greenwich LifeSciences in the second quarter worth $25,000. Finally, Geode Capital Management LLC lifted its position in Greenwich LifeSciences by 1.4% during the second quarter. Geode Capital Management LLC now owns 138,982 shares of the company’s stock valued at $1,261,000 after purchasing an additional 1,972 shares during the period. Hedge funds and other institutional investors own 4.16% of the company’s stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.